Compounded Semaglutide vs Brand-Name Wegovy: A 2026 Buyer's Guide

Compounded semaglutide is a version of the molecule prepared by a compounding pharmacy in response to an individual prescription. Compounding pharmacies are allowed to make a drug when there is a documented clinical need that the FDA-approved product cannot meet, such as when a patient is allergic to an inactive ingredient, needs a different concentration, or when the brand is in shortage. Between 2022 and early 2025, semaglutide was on the FDA shortage list, and compounding pharmacies legally produced large volumes for telehealth weight-loss programs. The FDA officially removed semaglutide from the shortage list in February 2025, narrowing the legal grounds for compounding.

Pricing varies widely by provider, but most reputable telehealth programs in 2026 charge between $150 and $400 per month for compounded semaglutide, often as a bundle that includes the consultation, the medication, and basic check-ins. Brand-name Wegovy lists at roughly $1,349 per month before discounts; Ozempic lists near $1,000. Novo Nordisk's NovoCare self-pay vials of Wegovy launched at $499 per month for those without insurance, reducing the price gap. Compounded options remain cheaper for many patients, especially those without commercial insurance or Medicare coverage for obesity drugs.

It depends on the pharmacy. The FDA has issued multiple warnings about compounded semaglutide, including reports of dosing errors, contamination, and the use of semaglutide salt forms (sodium or acetate) that have not been studied for safety or efficacy. The active pharmaceutical ingredient in brand Ozempic and Wegovy is semaglutide base, not a salt form. A 2024 FDA alert noted that adverse events from compounded GLP-1s, including hospitalizations, were rising. Pharmacies designated as 503B outsourcing facilities follow tighter Current Good Manufacturing Practice (cGMP) rules; 503A pharmacies follow state pharmacy boards and have more variable oversight. Always ask which category your pharmacy falls under.

Compounding remains legal under specific FDA rules but is more restricted than during the shortage. Pharmacies can still compound when a prescriber documents a medical reason that the commercial product is unsuitable, such as a true allergy to an inactive ingredient or a custom dose not made by Novo Nordisk. Mass-producing copies of an available drug for cost-saving alone is not a permitted reason. Several telehealth companies have transitioned to legitimate medical-necessity compounding, while others have moved patients to brand-name vials or to compounded tirzepatide, which is in a different regulatory position. State boards of pharmacy and the FTC have also begun investigating misleading marketing of compounded GLP-1s.

A reputable pharmacy will be willing to share its 503A or 503B status, the source of its active pharmaceutical ingredient (preferably FDA-registered), its sterility testing protocols, its beyond-use dating, and the prescriber's reasoning for medical necessity. Look for state pharmacy board licensure in your state, a physical pharmacist available for questions, and clear labeling of the drug form (semaglutide base vs salt). Avoid programs that mail medication without a real telehealth visit, that use vague labels like 'GLP-1 blend,' or that bundle the medication with vitamins or peptides like B12 in ways the FDA has flagged as concerning.

Tirzepatide was on the FDA shortage list and was removed in late 2024. The FDA later resolved litigation about the timeline, and compounding remains restricted to legitimate medical-necessity cases. Retatrutide, an investigational triple agonist from Lilly, is not approved by the FDA, and any pharmacy claiming to compound it is operating outside legal channels. Patients should be especially cautious about programs offering experimental molecules or unapproved peptides marketed as 'next-generation GLP-1s.'

If your insurance now covers brand semaglutide or Wegovy, switching is often safer because the drug, dose, and sterility are FDA-verified. The transition is straightforward at the equivalent dose. If you cannot access brand pricing, talk with your healthcare provider about whether a NovoCare vial, a Lilly Zepbound vial, or a documented medical-necessity compound is the right path. Coverage rules and self-pay programs change frequently, so it is worth re-checking every few months.